New peer review empirical research, published in the American Journal of Health Economics, finds that at least seven percent of Indian medicines are substandard. My colleagues and I procured 1470 medicines to treat infectious diseases across 22 emerging nation cities. The distribution of failure is not random, some Indian drug companies segment their markets based on quality sending substandard medicines to poorly regulated markets, such as in Africa. As Indian Prime Minister Narendra Modi visits Washington DC next week (June 7th/8th), we hope that Congressional leaders push him to improve oversight of this industry—the largest exporter of generic medicines in the world.
Read Full Article »
